# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Bloomberg
Eli Lilly reports detailed results from the SYNERGY-NASH phase 2 study. The trial, involving 190 patients with and without type...
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously pub...
Jefferies analyst Akash Tewari maintains Eli Lilly and Co (NYSE:LLY) with a Buy and raises the price target from $925 to $957.
Judge Karen Marston takes over the high-profile Ozempic litigation involving over 10,000 lawsuits. Here's the latest.
May labor market report: strong job gains and wage growth, reduces chances of rate cut. Interest-rate sensitive sectors underpe...
New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and t...